Table 1 Patient demographic with clinical data and outcomes

Number of infected persons

35

23

65

Age

 15-49Y

8 (22.9%)

0 (0.0%)

0 (0.0%)

 50-64Y

13 (37.1%)

1 (4.3%)

2 (3.1%)

 ≥ 65Y

14 (40.0%)

22 (95.7%)

63 (96.9)

Gender

 Male

16 (45.7%)

12 (52.2%)

35 (53.8%)

 Female

19 (54.3%)

11 (47.8%)

30 (46.2%)

Smoking history

 Non-smoker

18 (51.4%)

9 (39.1%)

32 (49.2%)

 Ex-smoker

2 (5.7%)

3 (13.1%)

5 (7.7%)

 Active-smoker

15 (42.9%)

11 (47.8%)

28 (43.1%)

COVID-19 vaccination status*

 Yes

9 (25.7%)

4 (17.4%)

14 (21.5%)

 No

26 (74.3%)

19 (82.6%)

51 (78.5%)

Comorbidities

 COPD

4

7

23

 HTN

28

19

36

 CHF

2

1

6

 DM

17

10

22

 CKD

1

0

3

 HC

3

2

4

 CI

4

3

10

aCCI**

5.49

6.13

5.24

Number of severe cases

4 (11.4%)

23 (100.0%)

48 (73.8%)

 Severe symptoms

 Pneumonia

4

23

48

 Liver function insufficiency

0

3

2

 Cardiovascular & cerebrovascular diseases

0

1

4

 Renal function impairment

0

1

2

 Rash

0

0

1

 Diarrhea

0

0

2

 Thrombocytopenia

0

0

1

 Thrombosis

0

0

0

Clinical outcomes

 Number of death

0 (0%)

12 (52.2%)

17 (26.2%)

 Mean time to symptomatic. alleviation (Days)

4.46

17.90

16.88

Changes of lymphocytes and neutrophils before and after infection (10^⁹/L) (Mean pre -and post treatment)

 Neutrophils

5.443/4.225

6.224/5.321

9.439/6.435

 Lymphocytes

1.224/1.237

1.346/1.358

1.201/1.390